HCA PE Ratio & Valuation,Is HCA Overvalued

HCA Relative Valuation

HCA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HCA is overvalued; if below, it's undervalued.

Historical Valuation

HCA Healthcare Inc (HCA) is now in the Overvalued zone, suggesting that its current forward PE ratio of 16.17 is considered Overvalued compared with the five-year average of 13.77. The fair price of HCA Healthcare Inc (HCA) is between 381.12 to 457.24 according to relative valuation methord. Compared to the current price of 470.60 USD , HCA Healthcare Inc is Overvalued By 2.92%.

Relative Value

Fair Zone

381.12-457.24

Current Price：470.60

2.92%

Overvalued

15.94

9.95

EV/EBITDA

HCA Healthcare Inc. (HCA) has a current EV/EBITDA of 9.95. The 5-year average EV/EBITDA is 8.95. The thresholds are as follows: Strongly Undervalued below 7.59, Undervalued between 7.59 and 8.27, Fairly Valued between 9.64 and 8.27, Overvalued between 9.64 and 10.32, and Strongly Overvalued above 10.32. The current Forward EV/EBITDA of 9.95 falls within the Overvalued range.

12.76

EV/EBIT

HCA Healthcare Inc. (HCA) has a current EV/EBIT of 12.76. The 5-year average EV/EBIT is 11.81. The thresholds are as follows: Strongly Undervalued below 10.02, Undervalued between 10.02 and 10.92, Fairly Valued between 12.71 and 10.92, Overvalued between 12.71 and 13.60, and Strongly Overvalued above 13.60. The current Forward EV/EBIT of 12.76 falls within the Overvalued range.

1.39

HCA Healthcare Inc. (HCA) has a current PS of 1.39. The 5-year average PS is 1.16. The thresholds are as follows: Strongly Undervalued below 0.89, Undervalued between 0.89 and 1.02, Fairly Valued between 1.29 and 1.02, Overvalued between 1.29 and 1.43, and Strongly Overvalued above 1.43. The current Forward PS of 1.39 falls within the Overvalued range.

9.31

P/OCF

HCA Healthcare Inc. (HCA) has a current P/OCF of 9.31. The 5-year average P/OCF is 7.94. The thresholds are as follows: Strongly Undervalued below 5.21, Undervalued between 5.21 and 6.57, Fairly Valued between 9.31 and 6.57, Overvalued between 9.31 and 10.67, and Strongly Overvalued above 10.67. The current Forward P/OCF of 9.31 falls within the Overvalued range.

15.14

P/FCF

HCA Healthcare Inc. (HCA) has a current P/FCF of 15.14. The 5-year average P/FCF is 14.62. The thresholds are as follows: Strongly Undervalued below 0.82, Undervalued between 0.82 and 7.72, Fairly Valued between 21.52 and 7.72, Overvalued between 21.52 and 28.42, and Strongly Overvalued above 28.42. The current Forward P/FCF of 15.14 falls within the Historic Trend Line -Fairly Valued range.

HCA Healthcare Inc (HCA) has a current Price-to-Book (P/B) ratio of -20.54. Compared to its 3-year average P/B ratio of -35.06 , the current P/B ratio is approximately -41.41% higher. Relative to its 5-year average P/B ratio of -22.08, the current P/B ratio is about -6.98% higher. HCA Healthcare Inc (HCA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 6.37%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 6.37% , the current FCF yield is about -100.00% lower.

-20.24

P/B

Median3y

-35.06

Median5y

-22.08

7.44

FCF Yield

Median3y

6.37

Median5y

6.37

Competitors Valuation Multiple

The average P/S ratio for HCA's competitors is , providing a benchmark for relative valuation. HCA Healthcare Inc Corp (HCA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 9.57%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of HCA increased by 56.52% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 14.03 to 18.19.

The secondary factor is the Margin Expansion, contributed 17.24%to the performance.

Overall, the performance of HCA in the past 1 year is driven by P/E Change. Which is more unsustainable.

9.57%

17.49B → 19.16B

Revenue Growth

17.24%

8.47 → 9.93

Margin Expansion

29.71%

14.03 → 18.19

P/E Change

56.52%

300.15 → 469.79

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is HCA Healthcare Inc (HCA) currently overvalued or undervalued?

What is HCA Healthcare Inc (HCA) fair value?

HCA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of HCA Healthcare Inc (HCA) is between 381.12 to 457.24 according to relative valuation methord.

How does HCA's valuation metrics compare to the industry average?

What is the current P/B ratio for HCA Healthcare Inc (HCA) as of Dec 17 2025?

As of Dec 17 2025, HCA Healthcare Inc (HCA) has a P/B ratio of -20.54. This indicates that the market values HCA at -20.54 times its book value.

What is the current FCF Yield for HCA Healthcare Inc (HCA) as of Dec 17 2025?

As of Dec 17 2025, HCA Healthcare Inc (HCA) has a FCF Yield of 0.00%. This means that for every dollar of HCA Healthcare Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for HCA Healthcare Inc (HCA) as of Dec 17 2025?

As of Dec 17 2025, HCA Healthcare Inc (HCA) has a Forward P/E ratio of 16.17. This means the market is willing to pay $16.17 for every dollar of HCA Healthcare Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for HCA Healthcare Inc (HCA) as of Dec 17 2025?

As of Dec 17 2025, HCA Healthcare Inc (HCA) has a Forward P/S ratio of 0.00. This means the market is valuing HCA at $0.00 for every dollar of expected revenue over the next 12 months.

HCA Valuation